Jefferies Reaffirms Their Buy Rating on Boston Scientific (BSX)
In a report released yesterday, Matthew Taylor from Jefferies maintained a Buy rating on Boston Scientific, with a price target of $67.00. The company’s shares closed yesterday at $46.06.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Taylor is a 4-star analyst with an average return of 6.9% and a 53.96% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific, GE Healthcare Technologies Inc, and Edwards Lifesciences.
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $68.68, a 49.11% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $65.00 price target.
Based on Boston Scientific’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.2 billion and a net profit of $1.34 billion. In comparison, last year the company earned a revenue of $4.66 billion and had a net profit of $674 million
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BSX in relation to earlier this year. Most recently, in May 2026, Edward Ludwig, a Director at BSX bought 3,580.00 shares for a total of $202,914.40.
Read More on BSX:
